Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.
Часто задаваемые вопросы
В каком секторе работает Ligand Pharmaceuticals Incorporated (LGND)?
Ligand Pharmaceuticals Incorporated относится к сектору Здравоохранение.
Какова текущая цена акций Ligand Pharmaceuticals Incorporated (LGND)?
По последним данным, цена акций Ligand Pharmaceuticals Incorporated составляет 308,30 $, предыдущее закрытие — 303,53 $. За последнюю торговую сессию акции Ligand Pharmaceuticals Incorporated выросли на 4,77 $, что соответствует росту на 1,57%.
Какой коэффициент цена/прибыль (P/E) компании Ligand Pharmaceuticals Incorporated (LGND)?
Текущий коэффициент P/E компании Ligand Pharmaceuticals Incorporated составляет 32,52, а прогнозный P/E — 25,76.
Выплачивает ли Ligand Pharmaceuticals Incorporated (LGND) дивиденды?
Нет, Ligand Pharmaceuticals Incorporated не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Ligand Pharmaceuticals Incorporated (LGND)?
У компании Ligand Pharmaceuticals Incorporated бета 0.983, что означает, что её волатильность примерно соответствует рыночной.
